|Bid||2.6200 x 45100|
|Ask||2.7000 x 3100|
|Day's range||2.4500 - 2.7200|
|52-week range||2.4500 - 11.1000|
|Beta (5Y monthly)||1.58|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
BOULDER, Colo., January 10, 2022--Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, 2021. The financial information presented in this news release may be adjusted as a result of completion of customary quarterly review and audit procedures.
BOULDER, Colo., December 09, 2021--Clovis Oncology Highlights FAP-2286 Preclinical Data Presented at the Targeted Radiopharmaceuticals Summit
BOULDER, Colo., November 03, 2021--Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2021, and provided an update on the Company’s clinical development programs and regulatory and commercial outlook.